Does size of telangiectasia on optical coherence tomography angiography influence vision in eyes with type 2 macular telangiectasia?
MacTel
Optical coherence tomography
telangiectasia
Journal
Indian journal of ophthalmology
ISSN: 1998-3689
Titre abrégé: Indian J Ophthalmol
Pays: India
ID NLM: 0405376
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
To study the influence of dimensions of macular telangiectasia (MacTel) on enface optical coherence tomography angiography (OCTA) on vision and clinical parameters in eyes with MacTel type 2. MacTel was classified based on OCTA location, i.e. either temporal to the fovea (grade 1), or spread nasally (grade 2), or circumferentially (grade 3), or the presence of neovascular-like tissue in the outer retina-choriocapillary complex (ORCC) (grade 4). On enface images, the maximum dimensions of the MacTel in the deep plexus were noted using calipers by a single experienced observer. Ninety-eight eyes of 49 patients with MacTel with a mean visual acuity was 0.46 + 0.26 logMAR and mean macular thickness of 202 ± 132 μ were included. Based on OCTA, grade 3 MacTel (n = 35, 36%) was the commonest followed by grade 4 (n = 28, 29%). The mean maximum vertical diameter of the MacTel was 2019 + 753 μ, and every 500 microns increment in vertical diameter of the MacTel was associated with a half-line drop in vision (95%CI = 0.005 to 0.08 logMAR, P = 0.03). Vision gradually reduced with increment in OCTA grades of MacTel from grade 1 to 3; however, the trend was not maintained in grade 4 MacTel, which showed better vision and lesser degenerative cysts. Larger telangiectasias were associated with significantly lower vision in MacTel. Eyes with deeper telangiectasia involving ORCC have better vision and evidence of far lesser neurodegeneration than type 3 disease, suggesting that this may not be part of the continuum and does not represent neovascularization.
Identifiants
pubmed: 34826997
pii: IndianJOphthalmol_2021_69_12_3570_331023
doi: 10.4103/ijo.IJO_315_21
pmc: PMC8837333
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3570-3576Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
None
Références
Ophthalmic Epidemiol. 2010 Jan-Feb;17(1):66-73
pubmed: 20100102
Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1381-1392
pubmed: 31093765
Retina. 2020 Jun;40(6):1132-1139
pubmed: 30893277
Middle East Afr J Ophthalmol. 2010 Jul;17(3):224-41
pubmed: 20844678
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT27-36
pubmed: 27409483
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT268-76
pubmed: 27409482
Retina. 2018 Oct;38(10):1920-1929
pubmed: 30095711
Turk J Ophthalmol. 2017 Oct;47(5):279-284
pubmed: 29109897
Prog Retin Eye Res. 2013 May;34:49-77
pubmed: 23219692
Arch Soc Esp Oftalmol (Engl Ed). 2018 Mar;93(3):105-112
pubmed: 29150217
Dev Ophthalmol. 2016;56:146-58
pubmed: 27022942
Retina. 2020 Jan;40(1):92-98
pubmed: 31246676
Semin Ophthalmol. 2017;32(3):384-394
pubmed: 27077639
Ophthalmic Epidemiol. 2013 Apr;20(2):109-13
pubmed: 23510315
Int Ophthalmol. 2019 Oct;39(10):2245-2256
pubmed: 30607862